These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12591377)

  • 1. A retrospective analysis of Neoral C2 monitoring in Chinese renal transplantation recipients.
    Tan J; Tang X
    Transplant Proc; 2003 Feb; 35(1):232-3. PubMed ID: 12591377
    [No Abstract]   [Full Text] [Related]  

  • 2. Conventional versus Neoral cyclosporine in renal transplantation.
    Rovelli E; Bucci A; Maldifassi P; Belfiore A; D'Amico G
    Transplant Proc; 1998 Aug; 30(5):1764-5. PubMed ID: 9723272
    [No Abstract]   [Full Text] [Related]  

  • 3. Experience with conversion from Sandimmun to Neoral cyclosporine and the correlation of C2 levels with renal function.
    Konstadinidou I; Boletis JN
    Transplant Proc; 2004 Mar; 36(2 Suppl):163S-166S. PubMed ID: 15041329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion at first rejection: a prospective trial comparing cyclosporine microemulsion with tacrolimus in renal transplant recipients.
    Dudley CR;
    Transplant Proc; 2001; 33(1-2):1034-5. PubMed ID: 11267179
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical experience with Prograf (tacrolimus, FK 506) in Chinese patients after renal transplantation.
    Yu L; Wang Y; Fu SJ; Cheng XJ
    Transplant Proc; 2000 Nov; 32(7):1709-10. PubMed ID: 11119902
    [No Abstract]   [Full Text] [Related]  

  • 6. Greater variability of dose-corrected cyclosporine C2 concentrations in renal recipients with acute rejection.
    Chueh SC; Liao CH; Lai MK
    Transplant Proc; 2003 Feb; 35(1):234-5. PubMed ID: 12591378
    [No Abstract]   [Full Text] [Related]  

  • 7. Neoral versus Sandimmune in kidney transplantation.
    Tisone G; Orlando G; Mercadante E; Vennarecci G; Pisani F; Buonomo O; Negrini S; Casciani CU
    Transplant Proc; 1998 Aug; 30(5):1749-50. PubMed ID: 9723265
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical study of sandimmun neoral in cadaveric renal transplantation.
    Xue W; Chen Y; Xing J; Tian P
    Transplant Proc; 1996 Jun; 28(3):1333-4. PubMed ID: 8658682
    [No Abstract]   [Full Text] [Related]  

  • 9. Conversion from Sandimmune to Neoral in renal transplant recipients: two-year experience.
    Wilczek HE; Akesson P; Warholm C
    Transplant Proc; 1998 Aug; 30(5):1753-5. PubMed ID: 9723267
    [No Abstract]   [Full Text] [Related]  

  • 10. Neoral vs Sandimmun: interim results of a randomized trial of efficacy and safety in preventing acute rejection in new renal transplant recipients. The U. K. Neoral Study Group.
    Lodge JP; Pollard SG
    Transplant Proc; 1997; 29(1-2):272-3. PubMed ID: 9122991
    [No Abstract]   [Full Text] [Related]  

  • 11. High performance liquid chromatography cyclosporine monitoring: a predictor of renal graft outcome.
    Cicciarelli J; Avila D; Iwaki Y; Sather H; Mendez R
    Transplant Proc; 1998 Aug; 30(5):1683-4. PubMed ID: 9723243
    [No Abstract]   [Full Text] [Related]  

  • 12. Neoral (cyclosporine) C2 monitoring in renal transplant recipients: a single-center experience in Asia.
    Wong HS; Morad Z
    Transplant Proc; 2003 Feb; 35(1):230-1. PubMed ID: 12591376
    [No Abstract]   [Full Text] [Related]  

  • 13. Conversion from cyclosporine Sandimmune to cyclosporine Neoral in the stable renal transplant population.
    Griffin PJ; Moore RH; Jurewicz WA; Lord RH; Webley Y; Jenkins J
    Transplant Proc; 1997; 29(1-2):303. PubMed ID: 9123007
    [No Abstract]   [Full Text] [Related]  

  • 14. Preoperative induction therapy with oral cyclosporine for recipients of living-related renal transplants.
    Rudich SM; Bhaduri S; Chang T; Cahn J; Katznelson S; Perez RV
    Transplant Proc; 1998 Jun; 30(4):1339-42. PubMed ID: 9636545
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety and effectiveness of microemulsion cyclosporine in renal allograft recipients: 1-year follow-up study.
    Park K; Kim MS; Kim SI; Kim YS; Moon JI
    Transplant Proc; 1998 Nov; 30(7):3556-7. PubMed ID: 9838557
    [No Abstract]   [Full Text] [Related]  

  • 16. The impact of cyclosporine on the development of immunosuppressive therapy: perspective from a transplant nephrologist involved with the development of C2.
    Cole E; Deshpande R
    Transplant Proc; 2004 Mar; 36(2 Suppl):408S-413S. PubMed ID: 15041376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C2 single-point sampling to evaluate cyclosporine exposure in long-term renal transplant recipients.
    Citterio F; Scatà MC; Borzi MT; Pozzetto U; Castagneto M
    Transplant Proc; 2001; 33(7-8):3133-6. PubMed ID: 11750347
    [No Abstract]   [Full Text] [Related]  

  • 18. Early cyclosporine concentration as predictor of graft survival in cadaveric renal transplantation.
    Salmela K; Kyllönen L
    Transplant Proc; 2001 Jun; 33(4):2441-3. PubMed ID: 11406202
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety and tolerability of Neoral vs Sandimmune: 1-year data in primary renal allograft recipients. Neoral Study Group.
    Barone G; Bunke CM; Choc MG; Hricik DE; Jin JH; Klein JB; Marsh CL; Min DI; Pescovitz MD; Pollak R; Pruett TL; Stinson JB; Thompson JS; Vasquez E; Waid T; Wombolt DG; Wong RL
    Transplant Proc; 1996 Aug; 28(4):2183-6. PubMed ID: 8769194
    [No Abstract]   [Full Text] [Related]  

  • 20. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.
    Alloway RR; Russell WC; Gaber LW; Amiri MH; Vera SR; Gaber AO
    Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.